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Abstract 
Objective. To examine gender differences in the characteristics and prevalence of 
various categories of glucose tolerance in a population study in Mauritius. 
Research Design and Methods. In 1998 a community-based cross-sectional survey was 
conducted in Mauritius. Categories of glucose metabolism were determined in 5,388 
adults, with an oral glucose tolerance test given to those who did not have previously 
diagnosed diabetes (n=4036). Other cardiovascular risk factors were assessed among 
those without known diabetes. 
Results. For men and women the prevalence of diabetes (22.0% vs. 21.8% respectively) 
and the prevalence of co-existing impaired fasting glucose (IFG) and impaired glucose 
tolerance (IGT) (3.2% vs. 2.9%) were similar.  However, men were twice as likely as 
women to have isolated IFG (5.1% (4.2-6.0) vs. 2.9% (2.3-3.5)), despite being younger, 
thinner and with lower plasma insulin but higher lipids. Conversely, the prevalence of 
isolated IGT was lower in men (9.0% (7.9-10.2) vs. 13.9% (12.6-15.1)).  Among non-
diabetic individuals, fasting glucose was higher in men than women, whereas 2-hour 
glucose was higher in women. In people without diabetes, women had significantly 
higher body mass index, beta cell function (HOMA-B), fasting and 2-hour insulin than 
men and significantly lower waist-hip ratios, waist circumference, insulin sensitivity 
(HOMA-S) and triglycerides.  
 
Conclusion. In Mauritius the distribution of impaired glucose metabolism differs by sex.  
The observation that IFG is more prevalent in men and IGT more prevalent in women 
raises important questions about their underlying aetiology and the ability of the current 
glucose thresholds to equally identify men and women at high-risk of developing 
diabetes. IFG should be seen as a complimentary category of abnormal glucose 
tolerance, rather than a replacement for IGT. 
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Introduction 
The most recent reports from the American Diabetes Association (ADA)1 and World 
Health Organization (WHO) consultation2 on diagnosis and diagnostic criteria for 
diabetes include categories of impaired glucose metabolism.  These categories identify 
persons with elevated fasting and/or post-load  blood glucose concentrations which have 
been shown to be associated with high risk of progression to diabetes3-6 as well as risk of 
future cardiovascular disease6-10.  
 
It is already apparent that there are significant differences between impaired fasting 
glucose (IFG) and impaired glucose tolerance (IGT), both in their respective prevalence 
within a population, and in the classification of individuals5, 11. Furthermore, it also 
appears that there might be some sex differences, with IGT being more common in 
women and IFG more common in men. We set out to explore this sex difference further, 
as it may have important implications both for the understanding of the pathogenesis of 
abnormal glucose metabolism and for the methods of screening men and women for this 
condition.  The implications for screening are highly pertinent, especially since the ADA 
proposes the use of fasting plasma glucose (FPG) alone, which cannot identify IGT. 
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Research design and methods 
Background and subjects 
Data collected in a population-based study conducted in Mauritius in 1998 were used to 
determine the prevalence of impaired glucose metabolism in men and women and to 
compare the phenotypic characteristics of the different categories.  Mauritius is an 
Indian Ocean island nation approximately 800km east of Madagascar. The population 
consists of 70% Asian Indians (both Hindus and Muslims), 2.1% Chinese and 27.9% 
“general population” who are predominantly people of African ancestry (Creoles) with 
varying amounts of European, Malagasy and Indian admixture. We have previously 
reported the high prevalence of diabetes, (almost universally type 2) in Mauritius12. All 
persons over 24 years of age living in selected areas, which have been described in detail 
elsewhere12, 13, were invited to attend the survey and the response rate was 80%. In 
addition, individuals who no longer resided in the selected areas but who had 
participated in similar surveys in 1987 and 1992 were invited to participate. The survey 
protocol was reviewed and approved by the local ethics committee (Melbourne, 
Australia) as well as the Ministry of Health, Mauritius. 
 
Survey procedures 
Each survey participant who had not previously been diagnosed with diabetes was asked 
to complete a 75gm oral glucose tolerance test (OGTT) (75g dextrose monohydrate in 
250ml water, replicating the procedure used in both the 1987 and 1992 Mauritius 
surveys12, 13) after an overnight fast. Blood was centrifuged, separated and the plasma 
was frozen on-site. Plasma glucose was measured using a YSI2300 analyzer (Yellow 
Springs, OH) approximately four months later in Newcastle upon Tyne, UK at the 
reference laboratory, which is a member of the Wellcome quality assurance scheme. In 
the 2 previous surveys (1987 and 1992), glucose was measured on-site, with quality 
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controls measured several months later in Newcastle upon Tyne using a YSI analyzer 
(Yellow Springs, OH). This showed a small, but consistent and systematic fall in 
glucose over time. Therefore, the 1998 values were adjusted upwards using an equation 
based on the difference between on-site values and quality controls from the 1987 and 
1992 surveys (n=2328 paired samples; adjusted glucose = 0.0288 + 1.037 x measured 
glucose; r2=0.981). Glucose tolerance status was determined according to 1999 WHO 
criteria2. Of the 6291 participants 154 were of Chinese origin, 38 were pregnant and 3 
were aged under 25 years. These people were excluded from the analyses. Of the 6096 
remaining study participants, 1352 had diabetes and a further 708 had missing FPG or 
2hPG results. Analyses of the glucose categories of those without diabetes include the 
remaining 4036 people.  Demographic data, physical measurements and questionnaires 
about lifestyle, medical history and health knowledge and attitudes were completed for 
each person. Prevalences, age and gender standardized to the 1998 Mauritius 
population14 for those aged over 30 years (age standardization was only performed on 
the population aged over 30 years because of the very low numbers of people in the 25-
29 year age group), were calculated for normal glucose tolerance (NGT), isolated IFG, 
isolated IGT, coexisting IFG/IGT and diabetes by sex.  The characteristics of men and 
women in each category of impaired glucose metabolism were compared to determine if 
the conditions being described are consistent across sexes. 
 
As IFG and IGT are not mutually exclusive categories, persons with IGT may or may 
not have IFG. In this study comparisons were made between individuals with isolated 
IFG and those with isolated IGT.  Persons defined as having isolated IFG had a FPG 
concentration ≥ 6.1 and < 7.0 mmol/l and a 2hPG < 7.8 mmol/l and those with isolated 
IGT had a 2hPG ≥ 7.8 and < 11.1 mmol/l and a FPG < 6.1 mmol/l.  Subjects with FPG ≥ 
6.1 and < 7.0 mmol/l and a 2hPG ≥ 7.8 and < 11.1 mmol/l were designated as having co-
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existing IFG/IGT.  Persons were defined as having diabetes if they were taking either 
insulin or oral medication for the control of diabetes or if they had a FPG ≥ 7.0 mmol/l 
and/or a 2hPG ≥ 11.1 mmol/l. The difference between individual fasting and 2-hour 
glucose values was calculated as 2hPG (mmol/l) – FPG (mmol/l). 
 
Total cholesterol and triglycerides were determined on fasting blood by manual 
enzymatic methods. Blood pressure was measured with a standard mercury 
sphygmomanometer in the right arm of participants who had been seated for 5-minutes.  
Using the first and fifth Korotkoff sounds, blood pressure was recorded twice to the 
nearest 2 mmHg and the mean value was calculated. Hypertension was diagnosed on the 
basis of WHO criteria15 (systolic blood pressure ≥140 mmHg and/or diastolic blood 
pressure ≥90 mmHg) or on self reported antihypertensive medication taken in the past 
week. Height and weight were measured in light clothing without shoes, and BMI was 
calculated as weight(kg)/height(m)2.  Waist circumference (WC) was measured at the 
horizontal level between the xiphisternum and umbilicus yielding the minimum 
measurement. Hip circumference was taken as the horizontal measure around the pelvis 
at the point of maximal protrusion of the buttocks.  Waist and hip circumference were 
measured twice, and the mean calculated. If duplicate waist or hip measurements 
differed by >2 cm, a third was taken. The mean of the closest two measurements was 
subsequently used. Waist-hip ratio (WHR) was calculated as the mean waist 
measurement divided by mean hip measurement.  Both WC and WHR were investigated 
as measures of central obesity. The modified homeostatic model16 was used to estimate 
beta cell function (HOMA-B) and insulin sensitivity (HOMA-S).  
 
Statistical analyses 
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All analyses were conducted using SPSS version 10.0.5 (SPSS Inc., Chicago). 
Triglycerides, glucose, weight and insulin values were log transformed before 
calculating (geometric) means.  Chi-squared tests were used to compare proportions and 
means were compared using Student’s t-tests. Both unadjusted glucose values, and 
values adjusted for the difference between QC and on-site glucose measurements from 
the 1987 and 1992 surveys were used to examine the difference in the relationship 
between fasting and 2-hour glucose values in men and women. Univariate general linear 
models were applied to calculate and compare mean FPG and 2hPG levels for each sex 
adjusted for fasting and 2-hour insulin, triglycerides and either BMI or WHR. Various 
other parameters were included in the models to see if they could explain sex differences 
in the glucose values. 
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Results 
 
Table 1 shows the prevalence of different states of glucose intolerance in Mauritius by 
sex. There were no significant differences in mean age or age distribution across decades 
for men compared with women. The distribution of the population over the glucose 
categories differed significantly by ethnic group (χ2 (4 d.f.) = 9.5, p=0.049) with Indians 
more likely to have diabetes and Creoles more likely to have IFG or IGT. Within each of 
the ethnic groups there were similar sex differences in the percent in each glucose 
category (Indians p=0.0001, General Population p=0.001). The prevalence of diabetes 
and co-existing IFG/IGT was similar in men and women, however, men were more 
likely than women to have isolated IFG (5.3 vs 3.1%, p<0.001). Conversely, the 
prevalence of isolated IGT was lower in men (9.3%) than in women 13.9% (p<0.0001).  
These findings were the same when either adjusted or unadjusted glucose values were 
used (data not shown). 
 
Comparisons of the characteristics of non-diabetic men and women within different 
categories of glucose tolerance are shown in Table 2. With the exception of females 
being slightly older than males among those with IFG, there were no significant 
differences between the sexes for age or prevalence of hypertension within the four non-
diabetic glucose categories.  Men and women with NGT differed significantly from each 
other on all other characteristics, with women having significantly higher 2hPG, fasting 
and 2-hour insulin, BMI and HOMA-B and significantly lower FPG, WC, WHR, 
weight, HOMA-S, triglycerides and total cholesterol than men. With the exception of 
FPG and 2hPG (which are used as the basis for categorization), similar patterns were 
seen in each of the other glucose tolerance categories. 
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When men with isolated IFG were compared with men with isolated IGT their FPG and 
2hPG, 2-hour insulin, WC, BMI and HOMA-B differed significantly (each with p-value 
at least <0.05).  Comparison between women in the isolated IFG and IGT groups 
showed they did not differ significantly for WC, or BMI but were significantly different 
for the other factors that differed in men i.e. FPG, 2hPG, 2-hour insulin and HOMA-B 
(p<0.001), as well as WHR (p = 0.02). 
 
Men had significantly higher mean FPG (p<0.001) and significantly lower 2hPG 
(p<0.001) than women. These differences remained highly significant (p<0.01) even 
after adjusting for all other variables in Table 2. 
 
Figure 1 shows the mean 2hPG value for any given FPG in the non-diabetic range for 
men and women. When grouped into 0.5 mmol/l categories of FPG, the mean 2hPG was 
significantly higher in women than men for each group (p<0.05). The mean difference 
between FPG and 2hPG was greater for women than for men (1.41 mmol/l vs. 0.65 
mmol/l, p<0.001).  It remained significantly greater for women both after adjustment for 
age, 2-hour and fasting insulin, HOMA-B, HOMA-S, triglycerides, obesity and weight 
(1.15mmol/l vs. 0.99mmol/l, p<0.01), and adjustment for age and weight only (1.47 vs. 
0.57, p<0.0001). 
 
When only FPG values were considered irrespective of diabetes status based on the 
2hPG, the proportion with a FPG in the range 6.1 to 6.9 mmol/l was 13.4% in men and 
9.7% in women (p<0.0001).  Also, when only 2hPG was considered irrespective of 
diabetes status based on the FPG, the proportion with a value between 7.8 and 11.1 
mmol/l was 16.1% in men and 21.0% in women (p<0.0001). 
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Discussion 
 
Data from this population-based survey show distinct sex differences in the prevalence 
of IFG and IGT, with IGT being more common in women and IFG more common in 
men. Other recent epidemiological studies17-24 have also reported similar sex differences 
in the prevalence of IFG and IGT, and the majority of IGT studies reviewed by the 
WHO showed that IGT was more common in men than women25. Furthermore, we have 
now described a difference in the relationship between FPG and 2hPG in men and 
women that may contribute to this phenomenon.  
 
While there may be some overlap between IFG and IGT, it is now quite apparent that 
they identify different sub-populations5, 11, 26, 27. This is understandable in the context 
that IFG reflects the basal fasting state while IGT signals postprandial abnormalities. 
Even though it is now clear that IFG and IGT encompass different sub-populations, 
using glucose measurements alone it is difficult to differentiate between the precise 
underlying abnormalities of insulin resistance and ß-cell dysfunction which lead to the 
conditions28, 29. Therefore, although the new category of IFG may broaden the 
description of intermediate abnormal states in glucose metabolism, it should be seen as 
complementary to IGT rather than its replacement. Screening programs aimed at 
identifying people at risk of developing diabetes that rely solely on the FPG, chance 
missing a considerable proportion of the at-risk population, and if our observations are 
further confirmed, may result in a sex-biased selection of individuals. 
 
Previous studies looking at insulin resistance and beta cell function in IFG and IGT have 
produced conflicting results. Data from the Pima Indian studies suggest that IFG and 
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IGT are associated with similar abnormalities of insulin action, and that IFG is also 
associated with reduced insulin secretory capacity30, 31. This finding was supported in a 
recent paper from the United Kingdom28.  However, the Botnia study reported the 
opposite, with the IFG group displaying insulin resistance, whereas subjects with IGT 
had impaired secretory capacity19. Our data are in keeping with the findings from the 
Pima and UK populations, and show that both categories are insulin resistant, and that 
beta cell function is reduced in those with IFG, but not those with IGT. In Mauritius we 
found that men have lower levels of beta cell function and higher rates of IFG than 
women, and women have lower insulin sensitivity than men and higher rates of IGT. 
 
The 2hPG associated with any given FPG is higher in women than men in this 
population. This remained true even after adjusting for a range of factors, including 
body weight. Thus, these male-female differences are not simply a consequence of 
giving the same glucose load to smaller individuals (i.e. women). This contributes to the 
explanation of why there are differences in the proportion of men and women classified 
as having isolated IFG or isolated IGT.  By definition, people with isolated IFG must 
have a relatively small difference between their FPG and 2hPG, which can now be seen 
to be more likely to occur in men than women. Conversely, isolated IGT requires a 
relatively large difference between the glucose values – a situation more likely to occur 
in women. These differences are partially a consequence of the cut-off values of the 
classification criteria and the relationship between FPG and 2hPG in each of the sexes.  
However, in addition to the apparent difference in the relationship between FPG and 
2hPG by sex, we found significant differences in the proportion of men and women with 
a FPG in the range 6.1 to 6.9 mmol/l or a 2hPG between 7.8 and 11.1 mmol/l regardless 
of the other respective glucose value. Adjusting for obesity using BMI or WHR did not 
explain the sex differences in either FPG or 2hPG. The importance of these sex 
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differences lies not only in the number of persons classified into each category but also 
in whether or not men and women in a particular glucose category are at similar risk of 
developing diabetes and its associated complications. Despite the majority of studies 
showing a preponderance of IGT among women, it is true that a number of studies 
identify men as having a higher prevalence of IGT than women. It is not clear what 
factors might be influencing these results, with a number of geographically and 
ethnically diverse populations represented among the studies showing a male 
predominance.  
 
The sex difference in the prevalence of different glucose categories raises the possibility 
that the classifications as currently defined have different prognostic implications for 
men and women. Further studies are required to elucidate the sex differences in glucose 
metabolism, and to determine longitudinally whether the rates of adverse outcomes 
associated with IFG and IGT are similar in both sexes.  
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Table 1 Percent of population aged ≥30 years in each glucose category by sex* 
Glucose Category 
Men (N = 2358) Women (N = 3030) 
N % 95% CI N % 95% CI 
Normal 1320 60.7 58.7 – 62.7 1666 58.5 56.8 – 60.3 
Isolated IFG 125 5.1 4.2 – 6.0 95 2.9 2.3 – 3.5 
Isolated IGT 219 9.0 7.9 – 10.2 421 13.9 12.6 – 15.1 
IFG and IGT 90 3.2 2.4 – 3.9 100 2.9 2.3 – 3.6 
Diabetes 604 22.0 20.3 – 23.8 748 21.8 20.2 – 23.3 
* Age and gender standardized to the 1998 Mauritius population aged ≥ 30 years14 
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Table 2 Mean values or percent prevalence for characteristics of non-diabetic men and women within different glucose categories. 
Glucose category NGT  I-IFG  I-IGT  IFG/IGT  Total 
Sex M F  M F  M F  M F  M F 
N 1320 1666  125 95  219 421  90 100  1754 2282 
Age (years) 46.4 46.7  49.3 54.1‡  50.0 50.6  52.7 53.0  47.4 48.0 
FPG (mmol/l)* 5.2 5.1‡  6.4 6.4  5.45 5.37†  6.4 6.5  5.4 5.3‡ 
2hPG (mmol/l)* 5.3 5.9‡  5.7 6.3‡  8.6 8.8‡  9.0 9.3†  5.8 6.5‡ 
Fasting insulin (mmol/l)* 6.9 8.1‡  8.7 10.4†  9.7 11.1‡  9.6 12.9‡  7.4 8.8‡ 
2-hour insulin (mmol/l)* 28.4 46.5‡  30.7 52.5‡  91.3 104.4  69.2 91.5‡  34.6 55.9‡ 
Body mass index (kg/m2) 23.8 25.0‡  24.0 26.8‡  25.4 27.3‡  25.1 28.3‡  24.1 25.6‡ 
Waist circumference (cm) 84.9 77.5‡  86.7 81.9‡  89.6 83.5‡  90.0 85.1‡  85.9 79.1‡ 
Weight (kg)* 66.0 57.9‡  66.5 61.6‡  68.7 62.7‡  68.5 64.4  66.5 59.1‡ 
Waist-Hip ratio 0.89 0.79‡  0.91 0.80‡  0.92 0.82‡  0.93 0.82‡  0.90 0.80‡ 
HOMA-B (%)* 98.0 113.4‡  77.8 87.4†  113.9 128.1‡  81.6 98.8‡  97.3 114.1‡ 
HOMA-S (%) * 55.2 47.5‡  41.1 34.7†  39.1 34.4‡  37.5 28.1‡  50.8 43.2‡ 
Triglycerides (mmol/l)* 1.4 1.1‡  1.5 1.2‡  1.6 1.3‡  1.6 1.4†  1.4 1.1‡ 
Total Cholesterol (mmol/l) 5.1 4.6‡  5.3 4.8‡  5.4 4.9‡  5.5 5.3  5.1 4.7‡ 
Hypertension (%) 22.5 21.3  37.9 38.9  40.4 40.6  51.1 53.5  27.3 27.0 
 
NGT – normal glucose tolerance; I-IFG – isolated IFG; I-IGT – isolated IGT; IFG/IGT – co-existing IFG and IGT. 
* geometric mean  
†p<0.05  ‡p < 0.01. p-values are for comparison with men within the same glucose category 
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